Novonesis (Novozymes A/S)

H1 2026: Novonesis delivered strong 8% organic sales growth and increases full-year outlook

COPENHAGEN, Denmark – August 19, 2026. Novonesis delivered strong first half of 2026 at 8% organic sales growth. 2026 outlook: Organic sales growth increased to 7-8% (previously 5-7%), and the adjusted EBITDA margin expected at the higher end of the 37-38% range. Inaugural share buy-back program announced.

Ester Baiget, President & CEO: 

Highlights of our H1 2026 results:

• Strong broad-based organic sales growth of 8% (Q2: 9%) including ~1.5 pp negative effect from exiting certain countries. Price contributed close to 2 pp and revenue synergies contributed a good 1 pp.
• Food & Health Biosolutions grew 9% (Q2: 9%) organically driven by Food & Beverages and included ~3 pp negative effect from exiting certain countries; Planetary Health Biosolutions grew 7% (Q2: 9%) organically with both Household Care and Agriculture, Energy & Tech performing very well.
• Developed markets grew 8% (Q2: 8%) organically and emerging markets 8% (Q2: 11%) including ~4 pp negative effect from exiting certain countries.
• Adjusted EBITDA margin at 37.7% (Q2: 37.6%), 30bps (Q2: 120bps) higher than last year incl. currency headwind.
• Adjusted net profit excl. PPA increased 8% (Q2: 9%).
• NIBD/EBITDA at 1.8x, and free cash flow bef. acq. at 14% of sales. CAPEX-to-sales ratio at 9.7% as planned.
• 2026 outlook: Organic sales growth range increased to 7-8% (previously 5-7%). Full-year outlook includes a close to 1 pp negative effect from exiting certain countries. Adj. EBITDA margin expected at the higher end of the 37-38% range.
• Interim dividend for first six months of 2026 approved by Board of Directors at DKK 2.35 (EUR 0.31) per share.
• Inaugural multi-year share buyback program in a total amount of EUR 1 billion approved to be initiated during the second half of 2026 and expected to be completed by the end of 2029.
• As communicated on August 10, an agreement was signed to acquire the remaining 77% of MicroBioGen. 
  
  Here is the link to the investor call on Novonesis H1 2026 results on August 20 at 9:00 CET: Novonesis H1 2026
  
  Get in touch
  Media relations
  Benjamin Hjorth
  Senior Press Manager
  media-relations@novonesis.com
  +45 30 77 13 12
  
  Tobias Bjorklund
  Head of Investor Relations
  tobb@novonesis.com